Producción Científica UPeU

URI permanente para esta comunidadhttps://cris.upeu.edu.pe/handle/123456789/1

Examinar

Resultados de la búsqueda

Mostrando 1 - 10 de 64

Some of the metrics are blocked by your
consent settings
Novel Biomarkers for the diagnosis of diabetic nephropathy.
(2024-01-01)
;
Juan Carlos Quiroz
;
Jacsel Suárez
;
José Enrique López Paz
;
Pela J Roseboom
Diabetes mellitus and its complications are a known public health problem nowadays. Diabetic nephropathy is one of the main complications and the result of multiple mechanisms, including: activation of the renin-angiotensin-aldosterone system, formation of advanced glycation end products and chronic inflammation that led to glomerular and tubulo-interstitial damage producing mesangial expansion and glomerulosclerosis, which finally results in chronic kidney disease. Early detection of diabetic nephropathy is essential for adequate intervention to stop, or at least slow down its progression. Multiple markers have been described, not only the classic ones such as serum creatinine, urea, and albuminuria, but at this point also novel biomarkers such as neutrophil gelatinase-associated lipocalin, tumor necrosis factor 1 receptor and monocyte chemoattractant protein-1, among others. The aim of this article was to provide an update review of the role of biomarkers in the diagnosis of diabetic nephropathy.
Some of the metrics are blocked by your
consent settings
Proceso de vacunación contra la COVID-19 en América Latina y el Caribe
(2022-10-26)
Tomás Caycho‐Rodríguez
;
Miguel Gallegos
;
Some of the metrics are blocked by your
consent settings
COVID-19 vaccination process in Latin America and the Caribbean
(2022-10-26)
Tomás Caycho‐Rodríguez
;
Miguel Gallegos
;
Some of the metrics are blocked by your
consent settings
Sample size in quantitative instrument validation studies: A systematic review of articles published in Scopus, 2021
(2022-12-01)
BACKGROUND: Due to the range of conflicting criteria regarding minimum sample size needed for a scale/questionnaire validation study, the objective of this review is to analyze sample sizes used in published journal articles to contribute a pragmatic perspective to the discussion on sample sizes. METHODS: A sample of 1999 articles published in a Scopus-indexed journal about the validation of a scale or questionnaire during 2021 were analyzed for this study. Abstracts from these articles were tabulated by two data entry professionals and any discrepancies were reviewed by the author. The sample size data was grouped by highest quartile of the journal publishing the article and further sub-categorized based on the inclusion of medical patients or students in each study's population. RESULTS: From the total sample, 1750 articles provided sufficient information in their summary to determine the sample size used. Of these, the majority were published in quartile 1 (784) and quartile 2 (620) journals. Mean values by quartile ranged from 389 (quartile 3) to 2032 (quartile 1), but extreme outliers limited the usefulness of the simple mean. Thus, outlier-removed means were calculated, and in most cases, these sample size values were higher for studies involving students and lower for studies involving patients. DISCUSSION: This study is limited by its focus on a single database and by including all phases of validation from initial quantitative instrument design studies (which tend to have the lowest sample sizes) up to international macro-studies (which can have hundreds of thousands of participants.) Nevertheless, the results of this study provide an additional practical perspective for the academic discussion regarding minimum sample size based on accepted practice.
Some of the metrics are blocked by your
consent settings
Sample size in quantitative instrument-based studies published in Scopus up to 2022: An artificial intelligence aided systematic review
(2023-11-01)
Despite their popularity, quantitative instruments like Likert scales struggle with a practical issue for research projects - how many participants have to fill out the instrument? This study started with the data for 31,271 articles downloaded from Scopus and, after exclusions, reviewed the sample size used in 21,506 studies. Scimago highest quartile data was brought in for 1999-2021 and linked to the exported articles. Anthropic's Claude and Claude-Instant AI tools were used to analyze the journal article abstracts and extract the sample size information. Frequency distribution of sample size used are presented. Descriptive statistics such as maximum, average and trimmed averaged sample size values are presented by quartile of the journal where the article was published, range of years when the article was published, 3 common analyses which tend to increase sample size, and two population groups which have been shown to impact sample size. The study concludes with ranges for commonly used sample sizes based on a number of criteria. This is one of the first studies to use AI tools to assist in the analysis for a systematic review study.
Some of the metrics are blocked by your
consent settings
Metabolic Pathways of Alcohol in the Liver
(2015-04-16)
;
Hern�n Iturriaga
Some of the metrics are blocked by your
consent settings
Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson’s Disease Project
(2023-10-03)
;
Harutyun Madoev
;
Anna Aasly
;
Azlina Ahmad‐Annuar
;
Bashayer Al‐Mubarak
Parkinson's disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk factor. However, the vast majority of our present data on monogenic PD is based on the investigation of patients of European White ancestry, leaving a large knowledge gap on monogenic PD in underrepresented populations. Gene-targeted therapies are being developed at a fast pace and have started entering clinical trials. In light of these developments, building a global network of centers working on monogenic PD, fostering collaborative research, and establishing a clinical trial-ready cohort is imperative. Based on a systematic review of the English literature on monogenic PD and a successful team science approach, we have built up a network of 59 sites worldwide and have collected information on the availability of data, biomaterials, and facilities. To enable access to this resource and to foster collaboration across centers, as well as between academia and industry, we have developed an interactive map and online tool allowing for a quick overview of available resources, along with an option to filter for specific items of interest. This initiative is currently being merged with the Global Parkinson's Genetics Program (GP2), which will attract additional centers with a focus on underrepresented sites. This growing resource and tool will facilitate collaborative research and impact the development and testing of new therapies for monogenic and potentially for idiopathic PD patients.
Some of the metrics are blocked by your
consent settings
Post-covid in patients with obesity: a narrative review
(2025-02-18)
Janeth Vásquez-Granda
;
Jessy C. Tarrillo-Olivos
;
Naomy R. Pereyra-Urbina
;
Jose F. Santacruz
;
Yajahira M. Cabanillas-Carrero
Objective: This study aims to conduct a brief literature review on post-COVID-19 complications in obese patients.Design: A literature review based on a narrative synthesis.Data Sources: The databases consulted include Science Direct, Scopus, Scielo, Google Scholar, and PubMed.Study Selection: Multiple articles were selected, applying inclusion criteria focused on post-COVID-19 complications in obese patients, with publications ranging from 2020 to 2024. Irrelevant studies were excluded. The final selection included articles from 10 different countries.Data Extraction: From each study, key data were extracted, including research design, population characteristics, and main reported complications. The information was organized narratively to facilitate comparison of findings across studies.Results: Out of 261,357 articles, 15 relevant articles were selected for the review. These articles were published in 10 countries, as follows: Spain (3 middle-income and 1 lower-middle income), Italy (1 lower-middle income, 1 high-income, and 1 mixed-income), India (2 middle and lower income), Russia (1 middle income), Japan (1 high, middle, and low income), Germany (1 middle income), United States (1 middle income), Mexico (1 middle income), Brazil (1 middle income), and China (1 high and middle income). The findings indicate that socioeconomic inequalities tend to increase the risk of COVID-19-related mortality.Conclusion: COVID-19 is associated with type 2 diabetes, an increased risk of coronary problems, hypertension, and nerve damage such as polyneuropathy, affecting muscle strength and increasing the mortality rate in respiratory diseases such as COPD, leading to lung damage and fibrosis. Treatment should be comprehensive, including vaccines, respiratory exercises, and physiotherapy, where the drug Veklury (remdesivir) has shown efficacy in accelerating recovery and strengthening the immune system. Additionally, post-COVID conditions such as anxiety, depression, and persistent respiratory issues should be addressed.
Some of the metrics are blocked by your
consent settings
Emerging Opportunities for Expanded Cereals and Andean Grains for the Development of Innovative Foods
(2025-10-14)
;
Julio Vidaurre‐Ruiz
;
José Martín Ramos-Díaz
;
Ritva Repo‐Carrasco‐Valencia
Some of the metrics are blocked by your
consent settings
Exploring the Future of Extrusion with Andean Grains: Macromolecular Changes, Innovations, Future Trends and Food Security
(2025-01-18)
;
Julio Vidaurre-Ruiz
;
Laura Linares-García
;
Ritva Repo‐Carrasco‐Valencia

Producción Científica UPeU

Examinar

Filtros

Ajustes

Ordenar por

resultados por página

Resultados de la búsqueda